Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MIRA

MIRA Pharmaceuticals (MIRA)

MIRA Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MIRA
DateTimeSourceHeadlineSymbolCompany
06/10/20247:30AMPR Newswire (US)Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This YearNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/30/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/29/20247:45AMPR Newswire (US)Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled SubstanceNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/29/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/22/20244:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/21/20247:45AMPR Newswire (US)MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/20/20247:00AMPR Newswire (US)Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/13/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRAMIRA Pharmaceuticals Inc
04/02/20247:00AMPR Newswire (US)Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionNASDAQ:MIRAMIRA Pharmaceuticals Inc
03/21/202410:04AMPR Newswire (US)MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorNASDAQ:MIRAMIRA Pharmaceuticals Inc
03/07/20243:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
02/05/20247:30AMPR Newswire (US)MIRA Pharmaceuticals Provides Corporate UpdateNASDAQ:MIRAMIRA Pharmaceuticals Inc
01/17/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/27/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/27/20234:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/27/20234:27PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
12/18/20233:50PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MIRAMIRA Pharmaceuticals Inc
12/04/20237:00AMPR Newswire (US)MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsNASDAQ:MIRAMIRA Pharmaceuticals Inc
12/01/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/29/20237:00AMPR Newswire (US)MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%NASDAQ:MIRAMIRA Pharmaceuticals Inc
11/21/20239:42AMPR Newswire (US)MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/21/20239:09AMPR Newswire (US)MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20233:18PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20233:15PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20237:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
11/20/20237:00AMPR Newswire (US)MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2NASDAQ:MIRAMIRA Pharmaceuticals Inc
09/18/20237:30AMPR Newswire (US)MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotNASDAQ:MIRAMIRA Pharmaceuticals Inc
09/05/20237:31AMPR Newswire (US)MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication EffortsNASDAQ:MIRAMIRA Pharmaceuticals Inc
08/31/20237:31AMPR Newswire (US)MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development SummitNASDAQ:MIRAMIRA Pharmaceuticals Inc
08/29/202310:39AMPR Newswire (US)MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIRA